MI-773 TFA |
رقم الكتالوجGC78972
One-Click Copy Product Info
|
MI-773 TFA is an orally active, selective MDM2-p53 interaction inhibitor with a K i of 0.88 nM for MDM2.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1303609-37-1
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
In Vivo, MI-773 (10-100 mg/kg; p.o.; daily) TFA induces dose-dependent tumor growth inhibition and regression in the UM-PDX-HACC-5 adenoid cystic carcinoma model, with 100 mg/kg mediating a 127% TGI index and 86% tumor shrinkage via p53-dependent apoptosis[1]. MI-773 (100 mg/kg; p.o.; daily) TFA mediates significant tumor regression in the ACCx6 adenoid cystic carcinoma PDX model[1]. MI-773 (100 mg/kg; p.o.; daily) TFA mediates significant tumor regression in the ACCx9 adenoid cystic carcinoma PDX model[1].
References:
[1]. Warner KA, et al. Targeting MDM2 for Treatment of Adenoid Cystic Carcinoma. Clin Cancer Res. 2016;22(14):3550-3559.
[2]. Chen YL, et al. MI-773, a breaker of the MDM2/p53 axis, exhibits anticancer effects in neuroblastoma via downregulation of INSM1. Oncol Lett. 2021;22(6):838.
| Cas No. | 1303609-37-1 | SDF | |
| Formula | C31H35Cl2F4N3O5 | M.Wt | 676.53 |
| الذوبان | DMSO: 100 mg/mL (147.81 mM; Need ultrasonic) | Storage | Store at 4°C, sealed storage, away from moisture |
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.4781 mL | 7.3907 mL | 14.7813 mL |
| 5 mM | 295.6 μL | 1.4781 mL | 2.9563 mL |
| 10 mM | 147.8 μL | 739.1 μL | 1.4781 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.50% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)